Hot And Hotter: Lepu Takes $140m Leap Into China Immuno-Oncology Fray

 
• By Brian Yang

Established just a year ago, China's Lepu Biotech has raised a mighty $131m to develop immuno-oncology antibodies, while Shanghai-based Asieris has obtained worldwide rights to develop and commercialize Photocure's Cevira for cervical dysplasia.

GoldKeyInPuzzle_1200x675
LEPU LEAPS INTO CHINA IO ARENA ARMED WITH MASSIVE NEW FUNDING • Source: Shutterstock

More from China

More from Focus On Asia